sorafenib has been researched along with ave-8063 in 1 studies
Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (ave-8063) | Trials (ave-8063) | Recent Studies (post-2010) (ave-8063) |
---|---|---|---|---|---|
6,520 | 730 | 5,251 | 20 | 0 | 9 |
Protein | Taxonomy | sorafenib (IC50) | ave-8063 (IC50) |
---|---|---|---|
Tubulin beta-4A chain | Homo sapiens (human) | 3.85 | |
Tubulin beta chain | Homo sapiens (human) | 3.85 | |
Tubulin alpha-3C chain | Homo sapiens (human) | 3.85 | |
Tubulin alpha-1B chain | Homo sapiens (human) | 3.85 | |
Tubulin alpha-4A chain | Homo sapiens (human) | 3.85 | |
Tubulin beta-4B chain | Homo sapiens (human) | 3.85 | |
Tubulin beta-3 chain | Homo sapiens (human) | 3.85 | |
Tubulin beta-2A chain | Homo sapiens (human) | 3.85 | |
Tubulin beta-8 chain | Homo sapiens (human) | 3.85 | |
Tubulin beta-2B chain | Bos taurus (cattle) | 1.8333 | |
Tubulin alpha-3E chain | Homo sapiens (human) | 3.85 | |
Tubulin alpha-1A chain | Homo sapiens (human) | 3.85 | |
Similar to alpha-tubulin isoform 1 | Bos taurus (cattle) | 1.8333 | |
Similar to alpha-tubulin isoform 1 | Bos taurus (cattle) | 1.8333 | |
Tubulin alpha-1C chain | Homo sapiens (human) | 3.85 | |
Tubulin beta-6 chain | Homo sapiens (human) | 3.85 | |
Tubulin beta-2B chain | Homo sapiens (human) | 3.85 | |
Tubulin beta-1 chain | Homo sapiens (human) | 3.85 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Carda, M; Conesa-Milián, L; Falomir, E; Marco, JA; Murga, J | 1 |
1 other study(ies) available for sorafenib and ave-8063
Article | Year |
---|---|
Synthesis and biological evaluation as antiangiogenic agents of ureas derived from 3'-aminocombretastatin A-4.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Molecular Docking Simulation; Stilbenes; Urea; Vascular Endothelial Growth Factor Receptor-2 | 2019 |